Selective inhibition of cyclooxygenase‐2 inhibits colon cancer cell adhesion to extracellular matrix by decreased expression of β1 integrin

• Published in: Cancer science Vol. 96; no. 2; pp. 93 - 99
• Main Authors: Yazawa, Kentaro, Tsuno, Nelson H., Kitayama, Joji, Kawai, Kazushige, Okaji, Yurai, Asakage, Masahiro, Sunami, Eiji, Kaisaki, Shoichi, Hori, Nobukazu, Watanabe, Toshiaki, Takahashi, Koki, Nagawa, Hirokazu
• Format: Journal Article
• Language: English
• Published: 550 Swanston Street (PO Box 378) Carlton South, Victoria 3053 Australia Blackwell Science Pty 01.02.2005; Blackwell
• Subjects: Biological and medical sciences; Gastroenterology. Liver. Pancreas. Abdomen; Medical sciences; Original; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus; Tumors; Enzyme; Cyclooxygenase 2; Cell adhesion molecule; Malignant tumor; Adhesion; Colon cancer; Cancerology; β1 integrin; Digestive diseases; Intestinal disease; Extracellular matrix; Inhibitor; Oxidoreductases; Tumor cell
• ISSN: 1347-9032; 1349-7006
• DOI: 10.1111/j.1349-7006.2005.00022.x

High level expression of cyclooxygenase (COX)‐2 is reported in 80–90% of colorectal adenocarcinomas. In the recent years, selective inhibitors of COX‐2 have been developed, and are shown to effectively protect against cancer development and progression. Colon cancer cells, as well as the epithelial cells in general, are dependent on appropriate interactions with the extracellular matrix (ECM) proteins to achieve a number of important functions, such as proliferation, differentiation, invasion and survival. These interactions are mediated via a family of cell‐surface receptors called integrins, which interact with cytoskeletal proteins on the cytoplasmic side of the plasma membrane and thereby provide a link between the ECM and the cytoskeleton. In the present study, a high‐COX‐2 (high level COX‐2 expression) colon cancer cell line, HT‐29, and a low‐COX‐2 (low level COX‐2 expression), DLD‐1, were used to investigate the anticolon cancer effect of the selective COX‐2 inhibitor, JTE‐522. Moreover, to clarify its mechanisms of action, we focused especially on the ability to adhere to and to migrate on ECM. We could clearly demonstrate that, in addition to the decrease of the proliferative activity, JTE‐522 caused a dose‐dependent decrease in both the ability of colon cancer cells to adhere to and to migrate on ECM. These effects were, at least in part, dependent on the down‐regulation of β1‐integrin expression, which was evident in HT‐29, the high‐COX‐2 colon cancer cells, but not the low‐COX‐2, DLD‐1. In addition, prostaglandin E2 almost completely reversed the effect of JTE‐522, strongly suggesting the involvement of a COX‐2‐dependent pathway. In conclusion, for the first time, we could demonstrate the down‐regulation of β1 integrin caused by COX‐2 inhibition, with consequent impairment of the ability of cancer cells to adhere to and to migrate on ECM, which are crucial steps for cancer metastases to develop. (Cancer Sci 2005; 96: 93–99)